Paliperidone Palmitate
Brand name: Invega Sustenna
Rank #20 of 500 drugs by total cost
$832.3M
Total Cost
252,388
Total Claims
$832.3M
Total Cost
6,783
Prescribers
$3,298
Cost per Claim
14,341
Beneficiaries
278,371
30-Day Fills
$123K
Avg Cost/Provider
37
Avg Claims/Provider
About Paliperidone Palmitate
Paliperidone Palmitate (sold as Invega Sustenna) was prescribed 252,388 times by 6,783 Medicare Part D providers in 2023, costing the program $832.3M. At $3,298 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology